[Skip to Content]

Clinical Trials for Cancer Treatment

Cancer TypePrincipal InvestigatorKeyword OR
ClinicalTrials.Gov ID
 

You searched for Category (Lung): 18 trials found.

Click sort in the column header to sort records.
Study TitlePI
849-012: A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Read more
Stephen L Graziano, MD
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Read more
Sam Benjamin, MD
A Randomized Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SAbR) in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC), The STABLEMATES Trial
Read more
Jeffrey A Bogart, MD
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy-Induced Neuropathic Pain
Read more
Mary J Cunningham, MD
A081801-Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO
Read more
Stephen L Graziano, MD
A082002: A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or Without SBRT for PD-L1-Negative, Advanced Non-Small Cell Lung Cancer
Read more
Michael D Mix, MD
AFT-57: Randomized Phase II Trial of Neoadjuvant and Adjuvant Atezolizumab with or without Tiragolumab in Conjunction with Chemoradiotherapy for Unresectable Stage III NSCLC
Read more
Michael D Mix, MD
Alliance A151216 - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Read more
Stephen L Graziano, MD
D516FC00001 - A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2)
Read more
Jason M Wallen, MD
EA5182: Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Read more
Stephen L Graziano, MD
ECOG E4512 - A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Read more
Stephen L Graziano, MD
NRG-CC009: Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer
Read more
Michael D Mix, MD
NRG-GY022 - Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Read more
Alina Basnet
NRG-LU007: RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC: RAPTOR trial
Read more
Michael D Mix, MD
Pilot study of the safety and feasibility of administering concurrent systemic chemotherapy with accelerated hypofractionated radiation therapy in the treatment of medically inoperable T1b and T2 Non-Small Cell Lung Cancer
Read more
Michael D Mix, MD
S1827: MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
Read more
Michael D Mix, MD
S1914 - A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
Read more
Michael D Mix, MD
S2302 - PRAGMATICA - LUNG: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer
Read more
Stephen L Graziano, MD

Search Again

Top